Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981541 | 1.00 | CDC7 (0.40) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| Hydrochloric Acid SCHEMBL2681922 | 0.99 | CDC7 (0.39) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| SCHEMBL2449055 | 0.99 | CDC7 (0.39) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| SCHEMBL2449053 | 0.99 | CDC7 (0.39) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| Hydrochloric Acid SCHEMBL2681924 | 0.99 | CDC7 (0.39) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| Hydrochloric Acid SCHEMBL2449082 | 0.97 | CDC7 (0.38) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| Hydrochloric Acid SCHEMBL2449080 | 0.97 | CDC7 (0.38) | CDC7PIM1CSNK2BCSNK2A1SCN10A | |
| SCHEMBL10177443 | 0.93 | CHRNB2 (0.39) | SCN10ACHRNB2CHRNA7CHRNA4MKNK1 | |
| SCHEMBL882749 | 0.91 | CHRNB2 (0.38) | SCN10ACHRNB2CHRNA7CHRNA4MKNK1 | |
| SCHEMBL15105935 | 0.91 | CHRNB2 (0.38) | SCN10ACHRNB2CHRNA7CHRNA4MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2850075-B1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2850075-B1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9365549-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9206159-B2 | Piperazine-piperidine compounds as hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150252023-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-10 | — | — | US | disclosed |
| EP-2635571-B1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9066944-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8921372-B2 | Inhibitors of hepatitis C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130287731-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130287730-A1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-31 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012048421-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287730-A1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ZC3HAV1, ITPA, HAVCR2 | CDC7 2008/4885PIM1 941/4885CSNK2B 2906/4885 |
| US-20130287731-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HCCS | CDC7 589/4885PIM1 3181/4885CSNK2B 1109/4885 |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | CDC7 365/4885PIM1 2884/4885CSNK2B 1223/4885 |
| US-20150252023-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HCCS | CDC7 589/4885PIM1 3181/4885CSNK2B 1109/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | CDC7 490/4885PIM1 2327/4885CSNK2B 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.